why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat
300×250 Ad Slot

Drug FDA Status

Showing 50 of 139 result(s) (Page 5 of 14)
Drug Name: Bizengri

Active Ingredient: zenocutuzumab-zbco

Approval Date: 2024-12-04

Description: To treat non-small cell lung cancer and pancreatic adenocarcinoma 

Drug Name: Iomervu

Active Ingredient: iomeprol

Approval Date: 2024-11-27

Description: For use as a radiographic contrast agent

Drug Name: Rapiblyk

Active Ingredient: landiolol

Approval Date: 2024-11-22

Description: To treat supraventricular tachycardia

Drug Name: Attruby

Active Ingredient: acoramidis

Approval Date: 2024-11-22

Description: To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis
Drug Trials Snapshot

Drug Name: Ziihera

Active Ingredient: zanidatamab-hrii

Approval Date: 2024-11-20

Description: To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer
Drug Trials Snapshot

Drug Name: Revuforj

Active Ingredient: revumenib

Approval Date: 2024-11-15

Description: To treat relapsed or refractory acute leukemia

Drug Name: Orlynvah

Active Ingredient: sulopenem etzadroxil, probenecid

Approval Date: 2024-10-25

Description: To treat uncomplicated urinary tract infections (uUTI)
Drug Trial Snapshot

Drug Name: Vyloy

Active Ingredient: zolbetuximab-clzb

Approval Date: 2024-10-18

Description: To treat gastric or gastroesophageal junction adenocarcinoma
Drug Trials Snapshots: VYLOY

Drug Name: Hympavzi

Active Ingredient: marstacimab-hncq

Approval Date: 2024-10-11

Description: To prevent or reduce bleeding episodes related to hemophilia A or B
Press Release
Drug Trials Snapshot

Drug Name: Itovebi

Active Ingredient: inavolisib

Approval Date: 2024-10-10

Description: To treat locally advanced or metastatic breast cancer
Drug Trials Snapshot

300×250 Ad Slot